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Abstract The mRNA's of several integrin subunits are alterna- 
tively spliced in the region encoding cytoplasmic domains, that 
may potentially provide alternative integrin-cytoskeleton i ter- 
actions and transmembrane signaling pathways. We identified a 
novel cytoplasmic tail variant of the human E1 subunit by reverse 
transcriptase polymerase chain reaction. This fourth i~1 variant, 
named 01D, is specific for skeletal and cardiac muscle. The 
determined genomic organization of the T-region of the human 
E1 gene reveals that/$1D is produced by alternative splicing of 
mRNA. In addition, we show that the expression of /]ID is 
developmentally regulated during murine myoblast differentia- 
tion, suggesting a role for/] ID in myogenesis. 
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I. Introduction 
Integrins constitute a family of heterodimeric transmem- 
brane glycoproteins, consisting of noncovalently associated 
and fl chains. The extracellular domains of both the ~ and fl 
subunits are involved in cellmxtracellular matrix or cellmell 
interactions and their cytoplasmic domains link the receptors 
to cytoskeletal proteins. Thus, integrins provide a link between 
the extracellular matrix and the cytoskeleton. In addition to 
adhesion, integrins have been shown to mediate signal 
transduction [1]. 
Sixteen ~ and eight fl subunits have thus far been identified 
and more than 20 combinations of these subunits have been 
reported. The diversity of the integrin family is further in- 
creased by alternative splicing of mRNAs, involving both the 
extracellular and cytoplasmic domains of integrin subunits. 
Splice variants of the cytoplasmic domain of both ~ and fl 
subunits have been reported: i.e. ~3, c~6, c~7, i l l ,  f13, andfl4 [1,2]. 
In both the fll and f13 subunits, alternative mRNA splicing 
leads to the production of different cytoplasmic domains after 
the conserved KWDT sequence, while in the ~3, c~6 and c~7 
subunits the alternative cytoplasmic domains deviate after the 
conserved cytoplasmic GFFKR amino acid sequence [3]. This 
alternative mRNA splicing is often tissue-specific. For exam- 
ple, the fl lB variant, which is produced by retention of intron 
sequences downstream of exon 6, carrying a new stop codon 
[4], is expressed only in skin and liver tissue, whereas the f l lC 
variant, which results from the insertion of an exon in the 
encoding mRNA, is expressed in haematopoietic cells [5]. Fur- 
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thermore, alternative mRNA splicing is developmentally regu- 
lated as in the case of c~6. The c~6B variant is already expressed 
in the preimplantated mouse embryo, whereas c~6A is expressed 
later on during embryogenesis [6,7]. 
Alternative splicing of the mRNA for the ~7 integrin is inter- 
esting with regard to myogenesis. Developmentally regulated 
splicing of the mRNA for the ~7 subunit occurs during the 
fusion of mononucleated myoblasts into multinucleated myo- 
tubes [8-10], a characteristic process in skeletal muscle differen- 
tiation. During this fusion process, the terminally differentiated 
muscle cells are withdrawn from the cell cycle and a set of 
muscle-specific genes is expressed. Subsequently, the myotubes 
mature to muscle fibers. In terminally differentiated skeletal 
muscle the major ~7A and c~7B and C integrin variants are 
expressed, whereas only the c~7B variant is present in myoblasts 
and heart [8]. 
In this study we have identified a new muscle-specific cyto- 
plasmic splice variant of the fll subunit, f l lD. Human f l lD 
cDNA was cloned from various muscle tissues, and the 
genomic organization of the 3'-region of the fll gene was deter- 
mined. Furthermore, we demonstrate hat the expression of the 
fl 1D variant is developmentally regulated uring murine C2C 12 
myoblast differentiation. 
2. Materials and methods 
2.1. Cells 
The murine myoblast cell line C2C12 (ATCC CRL 1772) was prop- 
agated in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 20% fetal calf serum, high glucose (4.5 g/l), penicillin and strepto- 
mycin. Terminal differentiation of confluent C2C12 monolayers to 
multinuclear myotubes was induced by changing the culture medium 
to DMEM containing 2% horse serum. 
2.2. cDNA synthesis and PCR 
First strand cDNA was prepared from 5 ¢tg total RNA of various 
human tissues using an oligo d(T)15 primer and the riboclone cDNA 
synthesis ystem (Promega, Madison, WI). To amplify the transmem- 
brane and cytoplasmic encoding regions of the human fl~ integrin sub- 
unit a sense primer (5'-GAACAACGAGGTCATGG-3'; positions 
2230-2246) and an antisense primer (5'-GCCCTAAAGCTACTACC- 
TAACTGTGAC-3'; positions 2553-2576 [11] ) were used. All polym- 
erase chain reactions (PCR) were performed in a final volume of 25 ¢tl 
containing: 20 mM Tris (pH 8.4), 50 mM NaC1, 1.5 mM MgCI> 1 mM 
of each dNTP, 80 ng of each primer and 1.0 U Taq polymerase (Life 
Technology). The PCR conditions were: 35 cycles of 1 min at 94 °C, 
1 min 30 s at 55°C and 30 s at 72°C. All PCR reactions described in 
this study had an initial denaturing step of 5 min at 94 °C and a terminal 
extension step of 5 min at 72 °C. The PCR products were digested with 
HindIII and ScaI. Subsequently, the fragments were isolated from a 
1.5% agarose gel and cloned into HindIII/Smal digested pUC18. Se- 
quencing of the subclones was done by using the dideoxy chain termi- 
nation method (Sequenase version 2.0 kit, USB, Cleveland, OH). 
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Total RNA from C2C12 cells was isolated at various time points after 
myotube induction, using the Ultraspec RNA kit (Biotecx Laboratories 
Inc, Houston. USA) as recommended by the manufacturer. Subse- 
quently, cDNA was prepared as described above using Superscript II
reverse transcriptase (Life Technology). Primers designed for identifica- 
tion of routine fllA and fllD were a sense primer (5'cggaattcGGCA- 
ACAATGAAGCTATCGT-Y; positions 2219 2238) and an antisense 
primer (5'-TGTCAGTCCCTGGCATG-3'; positions 2661-2677 [12]). 
Primers for the detection of murine c~3 were: a sense primer (5'-CAA- 
GTGGCTGCTGTATCCCACG-3'; positions 2554~2574 [13]) and an 
antisense primer (5'-gaatctagaTGCTCCCTGGAGGT-3' positions 
3824 3836 [14]). The c~3 products were further amplified by nested PCR 
with a sense primer (5'-CTCGGAGCTGGTGGAGGAGCT-3'; posi- 
tions 3487 3507) and an antisense primer (5'-TACTTGGGCATAA- 
TCCGGTAGTAG-3'; positions 3762 3786 [14]). Murine cc5 was am- 
plified by using a sense primer (5'-CTGCAGCTCCATTTCCGAGT- 
CTGG-3': positions 880 903) and an antisense primer (5'-GAAGCC- 
GAGCTTGTAGAGGACGTA-3'; positions 1132-1155 [15]); murine 
c~6: a sense primer (5'-GTCAGGTGTGTGAACATCAGG-3'; posi- 
tions 2975 2995) and an antisense primer (5'-CTGGAAAAAATAA- 
GGGGGGGC-3'; positions 3627 3647 [7]) and murine a7: a sense 
primer (5'-GTTGTGGAAGGAGTCCC- 3'; positions 184-200) and an 
antisense primer (5'-GTCTTCCCGAGGGATCTT- 3'; positions 447 
464 [9]). The additional nucleotides containing restriction-sites for clon- 
ing of the PCR products are indicated in lower-case l tters. 
The PCR conditions for the amplification of murine fllA and fllD, 
c~5 and the first PCR's for murine c~3 consisted of: 35 cycles of 1 min 
at 94 °C, 1 rain at 50°C, and 1 min at 72 °C. The nested PCR for c~3 
was 35 cycles of 1 rain at 94 °C, 1 min at 55 °C and 1 min at 72 °C. 
For murine c~6, 35 cycles of 45 s at 94 °C, 45 s at 50°C, 1 rain at 72°C 
were used. Murine c~7 cDNA was amplified by 35 cycles of 45 s at 94 
°C, 45 sec at 50°C and 30 s at 72°C. PCR products were analyzed on 
2% agarose gels. 
2.3. Genomic organization qf the 3' terminus of the fll gene 
Human genomic DNA was isolated by a standard procedure [15] and 
subjected to PCR. The following primer sets were used to define the 
exon/intron boundaries of the 3' part of the fll gene: a sense primer in 
the untranslated 3'end of fllB (5'-cggaattcTGGGGTAACCAAATG- 
TTGGC-3'; positions 1040-1059 [4]) and an antisense primer in exon 
D, (5"-cggaattcTCTTGAAATTATTAATAGGAC-3'); a sense primer 
in exon D, (5'-cggaattcGTCCTATTAATAATTTCAAGA-3') and an 
antisense primer in exon C (5'-cggaattcCTGGAAGTCAGAGGTT- 
GC-3'; positions 66 83 [5]). The additional nucleotides containing an 
EeoRI restriction-site are indicated in lower-case l tters. An antisense 
primer in exon 7 (positions 2553 2576 [11]) and sense primer in exon 
C (positions 66 83 [5]) were included in the initial screening for the 
genomic organization (see also Fig. 3A). 
PCR conditions were 35 cycles of 1 min at 94 °C, 90 s at 49°C and 
90 s at 72 °C. After EeoRI digestion of the 5' EcoRI flags the PCR 
products were subcloned into pUCI8 and sequenced as described 
above. 
3. Results 
3.1. IdentiJication of a fll isojorm specific jbr skeletal and 
cardiac muscle containing an alternative cytoplasmic domain 
Amplification by the reverse transcription polymerase chain 
reaction (RT-PCR) of mRNA extracted from various human 
tissues, with orimers flanking the transmembrane and cytoplas- 
mic encoding sequences of the fll cDNA,  revealed a band of 
347 bp in all tissues tested (Fig. 1). The size of this band 
corresponds to that predicted for the fll A cDNA sequence and 
sequence analysis confirmed that this PCR product encoded 
i l iA  [11]. An additional band of 428 bp was detected in skeletal 
and cardiac muscles. The PCR products from these tissues were 
cloned and sequenced. The sequence data obtained from three 
independent clones of both cardiac and skeletal muscles re- 
vealed the existence of a new, fourth fl l cytoplasmic domain 
variant (Fig. 2), which we named f l lD  according to the estab- 
~__~11D (428 nt) 
A (347 nt) 
g 
_../-[~1D (428 nt) 
~ I$1A (347 nt) 
Fig. 1. Expression offl lA andfllD mRNA in various tissues. RT-PCR 
was performed on RNA extracted l¥om tissues, using primers designed 
to amplify the/5'1 cytoplasmic domain. The 347 bp producl, correspond- 
ing to iliA, is present in all samples tested. The 428 bp product repre- 
sents the novel fllD variant and is exclusively expressed in skeletal 
muscle, heart muscle and myotubes. 
lished nomenclature. The f l lD specific sequence (81 bp) con- 
tains a translation stop codon and encodes the 24 C-terminal 
amino acids of the integrin subunit. Like the/31A variant,/31D 
contains three highly conserved cyto-sequences, cyto-1,-2 and 
-3, that are required for the localization of several fl-subunits 
in focal adhesions [16,17]. Comparison with the three previ- 
ously described fll splice variants, f l lA,  f l lB and fllC, shows 
that the f l lD is most similar to f l lA (Fig. 2B). In addition to 
the sequences encoding f l lA and f l lD, another minor PCR 
product of 284 bp was detected in stomach tissue. It encodes 
human pepsinogen C (98.6% identity) as was determined by 
sequencing (I-:ig. 1). 
3.2. Genomic oJ\~anization c~f fll D 
In order to localize the fll D specific sequence within the fll 
gene we determined the exon/intron boundaries of the 3'-region 
of this gene. Using genomic DNA as a template, we amplified 
the introns adjacent o the f l lD  exon. Primers located in the 
3'-untranslated end of f l lB cDNA and in the fllD-specific 
cDNA sequence (Fig. 3A, primers 1 and 2, respectively) re- 
vealed a 323 bp product. Primers located in the/q lD specific 
cDNA sequence and in the f l lC specific cDNA sequence 
(Fig. 3A, primers 3 and 4, respectively), yielded a 624 bp prod- 
uct. The PCR products were subcloned and sequenced as de- 
scribed in section 2. 
Sequence analysis revealed the localization of the f l lD spe- 
cific exon, exon D, between exon 6 and exon C (Fig. 3A). Figure 
3B shows the characterized exon/intron boundaries in the cyto- 
342 A. van der Flier et al./FEBS Letters 369 (1995) 340-344 
A 
(2119) 
(707) 
(2194) 
(732) 
(2269) 
(757) 
(2344) 
(782) 
(2419) 
(2492) 
GTGAATGGGAACAACGAGGTCATGGTTCAT G1-FGTGGAGAATCCAGAGTGTCCCACTGGT CCAGACATCATTCCA 
V N G N N E V M V H V V E N P E C P T G P D I I P 
ATT GTAGCT GGTGTGGTT GCT GGAATTGTT CTTATTGG CCl-F GCA1-FA CT GCTGATATGGAA GCT1-FTAAT GATA 
I V A G V V A G I V L I G L A L L L I W K L L M I 
ATT CAT GACAGAAGGGAGI-~ GCTAAATTT GA~GGAGA~T GAAT G( CAAAT G G GACAC G(AAGAAAAT CCG 
I H D3R ~ R E F A K F E K E K M N A K W D T 
~4 ................... 
AI~TACAAGAGTC CTATTMTAATTTCAAGAAT CCAAACTACG GA C GTAAAG CTG GT CT C taaat gccggt 9oa 
aotcctatttataagagtgccgtaacaactgtggtcaatccgaagtatgagggaaaatgogtactgcccgtgc 
2 
aaatcccacaacactgoatgcaaagtagcoatttccatagtcacagttaggtagctttagggcaatattgcea 
B 
BIA K L LMI I H ~A~K~NAKWDT GEN~SAVTTVV~EGK 
&IB KLLMI IH~F~NAKWDT VSYKTSKKQSGL 
~iC KLLMI IH~~NAKWDT SLSVAQPGVQWCDISSLQPLTSRFQQFSCLSLPSTWDYRVKIL FIRVP 
8ID KLLMIIHD~ NAKWDT QE~SPINNFK~RKAGL 
tyro- 1 cyto-2 cyto- 3 
Fig. 2. (A) The partial eDNA sequence and predicted amino acid sequence of the human '81D cytoplasmic variant. The putative trans-membrane 
region is lightly shaded and the '81D specific insertion (81 bp) is boxed and darkly shaded. Arrows indicate positions of primers used for cloning 
(primers 1 and 2), and those used for the localization of exon D in the'81 gene (primers 3 and 4). (Numbering of the nucleotide and deduced amino 
acid sequence starts at the reported translation start cod on offllA [11] ). (B) Alignment of alternative human fll cytoplasmic domains. The cytoplasmic 
domain amino acid sequences of'81A [11], '81B [4], '81C [5] and fllD are shown. The sequences diverge from the KWDT sequence after the first 26 
cytoplasmic amino acids. The conserved cyto-sequences are shaded [17]. The nucleotide sequence data are available from the EMBL Nucleotide 
Sequence Database under accession umber U28252. 
plasmic domain region of the fll gene; which all match the 
consensus plice donor and acceptor sequences, GT and AG, 
respectively [18]. Furthermore, Fig. 3A also shows the position 
of a polyadenylation sequence (AATAAA), situated 90 bp up- 
stream of exon D, which may function as a polyadenylation 
signal for the fllB variant. 
A 
Exon 6 
3.3. Expression of fllD during muscle differentiation 
Splice variants of ~7 that are exclusively expressed in muscle 
have been described [8,10]. The appearance of the c~7A splice 
variant in murine C2C12 myoblasts has been reported to coin- 
cide with differentiation to myotubes [9]. To analyze whether 
the expression of ill D is also correlated with muscle differenti- 
B S_~4 c A • 3~ 2 D , , -,,--6 
1----~ 
m ExonC - - -  Exon7 
_ I poly A 
B 
Exon 6 AAATGGGACACGg__taagttaco . . . . .  (1.23 kb, PCR) . . . .  tttactttQgCAAGAAAATCCG Exon D 
(165 bp) K W D T Intron 6/D - -  Q E N P (81 bp) 
Exon O GGTCTCTAAATTGCCgttcgtott...(481 bp, PCR) . . . . .  ttttgoocagTCTCTCTCTGTC Exon C 
(81 bp) G L * - -  Intron D/C - -  S L S V (116 bp) 
Exon C TGGGATTACAG . . . . . . . . . . . . . . . . . . . .  ( ? ) . . . . . . . . . . . . . . . .  GGTGAAAATCCTA Exon 7 
(116 bp) W D Y R not determined G E N P ~IA 
V K I L glC 
Fig. 3. Genomic organization of the 3'-region of the fll gene. (A) Schematic drawing of the 3'-region of the fll gene. Exons are boxed and numbered 
according to Lanza et al. [19], In thefl lA variant exon 6 is spliced to exon 7. fllB is not spliced, but arises from a skin and liver-specific readthrough. 
The fllB polyadenylation signal (AATAAA) that we located 90 bp upstream of exon D is indicated. The haematopoietic variant, fllC, contains a
116-bp insert (exon C), which induces a frame shift and a'81 C-specific translation stop in exon 7. The skeletal and cardiac muscle-specific '81D variant 
has exon D inserted at the same splice junction between exon 6 and exon 7. Arrows indicate the positions of oligonucleotides u ed for PCR analysis 
of the genomic organization. The putative transmembrane region is shaded and the translational stop codons of'81B, D, C, and A, respectively, are 
indicated by asterisks. (B) The exon/intron boundaries in the 3' terminus of the ,81 gene. Sizes of exons and introns are indicated between brackets. 
The consensus splice donor and acceptor sequences, GT/AG of each exon/introu border are underlined. 
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Fig. 4. RT-PCR amplification of iliA, ,BID, ~3, ~5, cz6, and c~7 in 
undifferentiated and differentiated (3 days) C2C12 cultures. The ex- 
pression of`BID (540 bp), ~3B (156 bp) and ~7A (281 bp) is differenti- 
ation stage-dependent, since fllD, u3B and ~7A specific PCR products 
are detectable in differentiated C2C12 cultures only. The mRNA's of 
`B1A (459 bp), ~3A (300 bp), ~z5 (275 bp), ¢¢6A (673), and ¢~7B (168 bp) 
subunits are expressed in both differentiated and undifferentiated 
C2C12 cells. 
ation we used murine C2C12 myoblast cells that forms myo- 
tubes in 2% horse serum. We were able to use murine cells in 
culture as a model, since the i l lD variant is also expressed in 
murine muscle (C. Baudoin, unpublished results). We also ana- 
lyzed, by RT-PCR, the expression of i l lA  and of various 
a- subunits that putatively form heterodimers with ill D (i.e. ~3, 
~5, ~6, and ~7) using cDNA prepared from both myoblasts and 
myotubes (3-day differentiated myoblasts). In undifferentiated 
C2C12 myoblasts, i l lA  as well as the ~3A, ~5, ~6A and ~7B 
cytoplasmic splice wtriants were detected (Fig. 4). Differenti- 
ated myoblasts additionally expressed the i l lD,  ~z3B and ~7A 
variants, while the expression of the other ~-subunits seemed 
to be unaltered. Analysis of these integrin subunits in C2C12 
cells, grown under differentiation-inducing conditions, showed 
that during muscle differentiation the decrease in i l lA  expres- 
sion coincides with an increase in i l lD and ~7A expression (not 
shown). 
4. Discussion 
In this report a new splice variant of the integrin i l l  subunit 
(ill D) is described which has an alternative cytoplasmic domain 
and is specifically expressed incardiac and skeletal muscle. This 
variant was detected by RT-PCR analysis in myotubes, skeletal 
and cardiac muscle tissue, but not in smooth muscle or other 
tissues, ill D appears to be the prominent ill isoform in adult 
skeletal and cardiac muscle. Since it is the fourth ill splice 
variant o date, the others being the ubiquitously expressed ill A 
and the much less widely expressed i l lB and fl lC variants, we 
named this novel variant ill D, Furthermore, xpression of the 
ill D splice variant is induced during C2C 12 myoblast differen- 
tiation into myotubes and this is accompanied by induction of 
:~3B and the previously reported ~7A variant [9]. 
Analysis of the genomic organization of the 3' terminus of 
the,81 gene by RT-PCR revealed an exon, named exon D, that 
encodes the specifically inserted sequence (81 bp) in i l lD  
cDNA. This exon is located between exon 6 [19] and thei l lC-  
specific exon [5]. In the f l lA variant three regions have been 
identified, named cyto-domain 1, 2 and 3 which contribute to 
integrin localization in focal contacts [17]. These cyto-domain 
sequences are highly conserved among the i l iA,  it2, il3A, it5, 
/36 and ]37 subunits. In addition, the observation that/31B and 
il3B splice variants, which both lack the cyto-2 and cyto-3 
domains, are not present in local contacts upports the notion 
that the cyto-domains are important for integrin localization in 
focal contacts [20,21]. i l lD contains all three cyto-sequences 
suggesting that ill D may also be localized in focal contact-like 
structures, e.g. in myotendinous and neuromuscular junctions 
or in intercalated discs in skeletal or cardiac muscle, respec- 
tively. Consistent with its assumed cellular localization, the 
cytoplasmic domain of il l D contains potential binding sites for 
~-actinin and talin. These cytoplasmic proteins are co-localized 
in focal contacts in cultured cells and they have been reported 
to bind to i l i a  in vitro [22,23]. The i l lD cytoplasmic domain 
differs t¥om the i l iA,  it2, and it3 in sequences between the two 
NPXY sequences. This part contains three related amino acids 
(VTT, TTT and TST) that have recently been implicated in the 
regulation of ligand affinity of integrins [24 27]. 
It has been reported that the function of the cytoplasmic 
domain of ill B, resulting from alternative splicing, is different 
from that of i l lA .  Cell adhesion mediated by fllB integrin to 
fibronectin and laminin is reduced as compared to that medi- 
ated by i l iA ,  and cells expressing ill B have a reduced motility 
[20,28]. The observation that ill D is upregulated during myo- 
blast differentiation points to a role in myogenesis. At this stage 
of investigation the function of the skeletal and cardiac muscle- 
specific ill variant is only hypothetical. A crucial role for ill D 
in myoblast fusion is unlikely since f l lD is also expressed in 
cardiac muscle in which, in contrast to skeletal muscle, multmu- 
cleated myotubes are not formed. In addition, the inhibitory 
effect of the CSAT antibody, directed against he cxtracellular 
part of chicken il l, on myotube fusion is likely to be due to a 
disturbance of adhesion before the actual fusion process 
[29,30]. However, the suggestion by Rosen et al. [31] that ~4ill 
and its ligand VCAM-I are involved in secondary myoblast 
fusion still allows a role for ill D in that stage of the process. 
Presumably, i l lD plays a role in the organization of the 
sarcomeric ytoarchitecture: its cytoplasmic domain may be 
involved in striated muscle-specific, myofibrillar protein-pro- 
tein interactions. This hypothesis i supported by the observa- 
tion that the loss ofilps, the fll-subunit homologue in Dro.so- 
p/illa, in the myo.wheriod mutant, leads to a disrupted Z-band 
formation [32]. In addition, several immunohistochemical stud- 
its [33 36] have shown that the localization of ~ill hetero- 
dimers at the myotendinous junction, which connects the 
myofibrils at the cellular end to the tendon, and at costamcres, 
structures that link the Z-disks to the sarcolemma in banded 
patterns, is regulated by :~-subunils (e.g. ~3, ~5, ~7 and 0~v). 
However, no ill variants have so Ihr been implicated in these 
studies. 
Association of ill D with ~-subunits i probably not affected, 
since the heterodimer formation is determined by the extracel- 
lular and transmembrane domains of the ,/3 subunit [37 39]. 
Association of ill D with the simultaneously expressed ¢t7A and 
~z3B subunit could result in muscle specific integrins with 
unique cytoplasmic domains. The association of ill D with a 
xariant ~-subunit, resulting from ahernativc splicing, could 
344 A. van der Flier et al./FEBS Letters 369 (1995) 340~44 
thus lead to the acquisition of signal transduction pathways in 
addition to the pp125 yAK phosphorylation cascade [40]. Anti- 
bodies against f l lD are currently being generated to test these 
hypotheses. 
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